Study SAKK 15/19 Radiation of lung tumor and maintenance therapy with durvalumab following treatment with chemotherapy and durvalumab in patients with advanced small cell lung cancer
Summary of the study
In this study, patients with small cell lung cancer (SCLC) in whom the disease has already spread are being examined. It is being investigated whether radiotherapy of the tumor together with the administration of the drug Durvalumab: - can slow down the progression of the disease - and whether this therapy is safe. The active substance durvalumab stimulates the body's own immune system to fight the tumor cells more effectively and is therefore known as immunotherapy. The additional radiation could strengthen this effect. Durvalumab is currently approved in Switzerland for the treatment of another form of lung cancer (non-small cell lung cancer). This is a national study being conducted at several hospitals in Switzerland. It is planned that 46 patients will take part in the study. The study treatment will last a maximum of two years and three months per study participant. In the following two years, the participants will be monitored regularly.
(BASEC)